Results 41 to 50 of about 77,108 (288)

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Case Reports in Oncology, 2016
Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma.
Marcus Messmer, Sunita Upreti, Yaman Tarabishy, Nikhilesh Mazumder, Reezwana Chowdhury, Mark Yarchoan, Matthias Holdhoff   +6 more
doaj   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma

Frontiers in Public Health, 2022
BackgroundThe treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM ...
Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li   +4 more
doaj   +1 more source

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

New England Journal of Medicine, 2023
BACKGROUND The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.
T. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Żurawski, Eduardo Yañez Ruiz, M. Maruzzo, A. Suárez Zaizar, L. Fein, F. Schutz, D. Heng, Fong Wang, F. Mataveli, Yu-Lin Chang, M. A. Van Kooten Losio, C. Suarez, R. Motzer   +17 more
semanticscholar   +1 more source

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Journal of Clinical Oncology, 2022
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care.
T. André, D. Tougeron, G. Piessen, C. de la Fouchardière, C. Louvet, A. Adenis, M. Jary, C. Tournigand, T. Aparicio, J. Desramé, A. Lièvre, Marie-Line Garcia-Larnicol, T. Pudlarz, R. Cohen, Salomé Memmi, D. Vernerey, J. Henriques, J. Lefèvre, M. Svrcek   +18 more
semanticscholar   +1 more source

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BMC Cancer, 2019
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma   +2 more
doaj   +1 more source

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

Journal of Translational Medicine, 2012
Background Ipilimumab and vemurafenib have both been shown to improve survival in phase III trials of patients with metastatic melanoma. Although vemurafenib is associated with a rapid onset of activity, responses are often of limited duration ...
Ascierto Paolo A, Simeone Ester, Giannarelli Diana, Grimaldi Antonio M, Romano Anna, Mozzillo Nicola   +5 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Ipilimumab cystic hypophysitis mimicking metastatic melanoma

Radiology Case Reports, 2018
Ipilimumab is an immunotherapeutic agent used in the treatment of metastatic melanoma, and is known to cause hypophysitis in some patients. Magnetic resonance imaging of ipilimumab-induced hypophysitis typically shows diffuse enlargement of the pituitary
John Wallace, BS, Martin Krupa, MD, James Brennan, MD, Frank Mihlon, MD   +3 more
doaj   +1 more source

18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

Cancer Imaging, 2020
Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma.
Annie Wong, Jason Callahan, Marleen Keyaerts, Bart Neyns, Johanna Mangana, Susanne Aberle, Alan Herschtal, Sonia Fullerton, Donna Milne, Amir Iravani, Grant A. McArthur, Rodney J. Hicks   +11 more
doaj   +1 more source

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

JAMA Oncology, 2020
Key Points Question Does adding ipilimumab to nivolumab improve clinical outcomes for patients with advanced hepatocellular carcinoma previously treated with sorafenib?
T. Yau, Yoon-Koo Kang, Tae-You Kim, A. El-Khoueiry, A. Santoro, B. Sangro, I. Melero, M. Kudo, M. Hou, A. Matilla, F. Tovoli, J. Knox, A. Ruth He, B. El-Rayes, M. Acosta-Rivera, Ho Yeong Lim, J. Neely, Yun Shen, T. Wisniewski, Jeffrey Anderson, Chiun Hsu   +20 more
semanticscholar   +1 more source